The effects of flavanoid on the treatment of hepatopulmonary syndrome

Basit Öğe Kaydı
dc.contributor.authorAtalay, Talha
dc.contributor.authorCakir, Murat
dc.contributor.authorTekin, Ahmet
dc.contributor.authorKucukkartallar, Tevfik
dc.contributor.authorKargin, Suleyman
dc.contributor.authorKartal, Adil
dc.contributor.authorKaynak, Adnan
dc.date.accessioned2024-02-23T14:38:01Z
dc.date.available2024-02-23T14:38:01Z
dc.date.issued2013
dc.departmentNEÜen_US
dc.description.abstractPurpose: Hepatopulmonary syndrome is an arterial oxygenation disorder brought about by advanced liver failure and pulmonary vascular dilatations. The reason why hypoxia develops in hepatopulmonary syndrome depends on the broadening of perialveolar capillary veins. Our study aims to investigate the effects of Flavanoid on hepatopulmonary syndrome through its inhibition of nitric oxide. Methods: Three groups, each having 8 rats, were formed within the scope of our study. Group I (the control group) only received laparatomy, group II received choledoch ligation, and group III was administered Flavanoid (90% flavonoid diosmin, 10% flavonoid hesperidin) following choledoch ligation. The rats were administered Flavanoid at week two following choledoch ligation. The rats' livers and lungs were examined histopathologically following a five-week follow-up and the perialveolar vein diameters were measured. Arterial blood gases and biochemical parameters were evaluated. Results: It was seen that fibrosis and oxidative damage in the liver with obstructive jaundice as well as hypoxia with pulmonary perialveolar vein sizes were significantly lower than the other group with cirrhosis formed through the administration of Flavanoid. Conclusion: We have concluded that Flavanoid administration might be useful in the treatment of hypoxia in hepatopulmonary syndrome and the delay of cirrhosis contraction.en_US
dc.identifier.doi10.4174/jkss.2013.85.5.219
dc.identifier.endpage224en_US
dc.identifier.issn2233-7903
dc.identifier.issn2093-0488
dc.identifier.issue5en_US
dc.identifier.pmid24266012en_US
dc.identifier.scopus2-s2.0-84892692037en_US
dc.identifier.startpage219en_US
dc.identifier.urihttps://doi.org/10.4174/jkss.2013.85.5.219
dc.identifier.urihttps://hdl.handle.net/20.500.12452/16331
dc.identifier.volume85en_US
dc.identifier.wosWOS:000326318100004en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherKorean Surgical Societyen_US
dc.relation.ispartofJournal Of The Korean Surgical Societyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHepatopulmonary Syndromeen_US
dc.subjectFlavanoiden_US
dc.subjectLiveren_US
dc.subjectLungen_US
dc.titleThe effects of flavanoid on the treatment of hepatopulmonary syndromeen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu